DongKook Pharmaceutical Co. Ltd (086450) - Total Liabilities
Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has total liabilities worth ₩299.16 Billion KRW (≈ $202.73 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DongKook Pharmaceutical Co. Ltd operating cash flow efficiency to assess how effectively this company generates cash.
DongKook Pharmaceutical Co. Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 086450 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
DongKook Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Excelliance MOS
TWO:5299
|
Taiwan | NT$753.56 Million |
|
Oncolytics Biotech Inc
TO:ONC
|
Canada | CA$13.88 Million |
|
Limes Schlosskliniken AG
XETRA:LIK
|
Germany | €20.16 Million |
|
Leifheit Aktiengesellschaft
F:LEI
|
Germany | €97.19 Million |
|
PT Satu Visi Putra Tbk
JK:VISI
|
Indonesia | Rp108.31 Billion |
|
Casa de Bolsa Finamex S.A.B. de C.V
MX:FINAMEXO
|
Mexico | MX$210.31 Billion |
|
Dynagas LNG Partners LP
NYSE:DLNG
|
USA | $313.01 Million |
|
Alan Allman Associates SA
PA:AAA
|
France | €285.92 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down DongKook Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 086450 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DongKook Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual total liabilities of DongKook Pharmaceutical Co. Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩299.16 Billion ≈ $202.73 Million |
+9.11% |
| 2024-12-31 | ₩274.19 Billion ≈ $185.81 Million |
+4.11% |
| 2023-12-31 | ₩263.36 Billion ≈ $178.48 Million |
-1.14% |
| 2022-12-31 | ₩266.39 Billion ≈ $180.53 Million |
-9.85% |
| 2021-12-31 | ₩295.51 Billion ≈ $200.26 Million |
+17.36% |
| 2020-12-31 | ₩251.80 Billion ≈ $170.64 Million |
+38.72% |
| 2019-12-31 | ₩181.51 Billion ≈ $123.01 Million |
+8.54% |
| 2018-12-31 | ₩167.22 Billion ≈ $113.32 Million |
+52.90% |
| 2017-12-31 | ₩109.37 Billion ≈ $74.12 Million |
+24.59% |
| 2016-12-31 | ₩87.78 Billion ≈ $59.49 Million |
+16.76% |
| 2015-12-31 | ₩75.18 Billion ≈ $50.95 Million |
+11.21% |
| 2014-12-31 | ₩67.60 Billion ≈ $45.81 Million |
+20.68% |
| 2013-12-31 | ₩56.02 Billion ≈ $37.96 Million |
-- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more